How big data and biomarkers are improving sepsis patient outcomes

/Dr. Ron Daniels

26 Jul 2021

Dr. Ron Daniels, Executive Director and Founder of the UK Sepsis Trust, discusses the four ways the UK Sepsis Trust looks to help improve outcomes from sepsis and patient care after diagnosis. Daniels explains the importance of using big data to discover sepsis trends within the population and highlights the benefits of using procalcitonin as a biomarker for pathogen identification within these patients.

Dr. Ron Daniels

UK Sepsis Trust

Biography

Ron Daniels is an NHS Consultant in Intensive Care, based in Birmingham, U.K. He’s also Executive Director of the UK Sepsis Trust and is Vice President of the Global Sepsis Alliance. In 2016, he was awarded the British Empire Medal for services to patients. Ron’s expertise lies in translational medicine and leadership. He leads the team driving dissemination of the Sepsis 6 treatment pathway and is part of the team responsible for much of the policy and media engagement around sepsis in the U.K. and elsewhere, including the adoption of the 2017 Resolution on Sepsis by the WHO. At home, Ron’s worked with the NHS over the past five years to ensure that, in England, more than 80% of patients presenting with suspected sepsis now receive appropriate antimicrobials rapidly. He’s ever mindful of the perceived conflict, and the synergies and need for collaboration, with the antimicrobial stewardship agenda.